https://doi.org/10.4081/hmr.v2i10.459

Darbepoietin alpha: pharmacokinetics and clinical use in neonates

Vol. 2 No. 10: Vth International Neonatal Hematology and Immunology Meeting
Published: June 9, 2009
Abstract Views: 284
PDF: 880
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

RK Ohls
support@pagepress.org
A Dai
M Roohi
Many hyporegenerative anemias in adults result from insufficient erythropoietin production, and the administration of recombinant human erythropoietin effectively stimulates red cell production. A biologically modified erythropoietic protein with a significantly longer half-life, darbepoetin alfa (Aranesp®), was developed by Amgen to allow for less frequent dosing. Studies in adults showed that darbepoetin alfa increased hemoglobin using once weekly to once every three week dosing. Studies evaluating the effectiveness of darbepoetin in treating other hyporegenerative anemias in adults and children are ongoing. Single dose pharmacokinetics have been determined in preterm infants, and phase II neonatal studies are in progress.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Ohls, R., Dai, A., & Roohi, M. (2009). Darbepoietin alpha: pharmacokinetics and clinical use in neonates. Hematology Meeting Reports (formerly Haematologica Reports), 2(10). https://doi.org/10.4081/hmr.v2i10.459
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).